Investigating the prescribing trend is important to improve rational prescribing. This study aimed at assessing the cardiovascular drug use, pattern, and its impact on clinical outcome. A cross-sectional study was employed in the outpatient department of chronic illness clinic of Gondar University specialized hospital, Ethiopia from 15 January 2017 to 15 March 2017. The independent variables were sociodemographic, medication, and other clinical information while cardiovascular disease improvement is the outcome variable. Binary logistic regression was used to test the association between the independent variables and the outcome variable. Kaplan Meier curve was used to analyze the clinical improvement while the Log-rank test was employed to compare the clinical outcome with the number of medications. Eight hundred thirtythree cardiovascular patient medical records were included in the final analysis. The majority (62.5%) of patients were females and more than 61% were above 50 years of age. Diuretics monotherapy accounted for a third (33.6%) of cardiovascular drug use, followed by combination therapy of angiotensin convertase enzyme inhibitors with Diuretics (21.8%) and calcium channel blockers with diuretics (8.3%). Cardiovascular patients followed for 72 months found to have a good level of clinical improvement on combination medication (Log Rank of 28.9, P = 0.000). In this study, diuretics monotherapy or in combination with angiotensin convertase enzyme inhibitors were found to be the frequently prescribed drugs in cardiovascular patients. Combination therapy has an implication for good cardiovascular improvement on long term follow-up. It seems clinicians were restricted to certain cardiovascular medications while plenty of choices are available from the diverse classes of cardiovascular drugs.
| INTRODUC TI ON
Cardiovascular disease (CVD) is a major health problem throughout the world and a common cause of early morbidity and mortality. In 2015, estimated 422.7 million CVD cases and 17.92 million CVD deaths have been occurred globally. In sub-Saharan Africa more than 1 million deaths per year and nearly half million deaths per year have been predicted in eastern Africa. 1 CVDs have emerged as the leading cause of mortality in developing countries accounting for 80% of cardiovascular deaths and responsible for the significant number of medical admissions in hospitals. [2] [3] [4] Ethiopia is in the state of epidemiological transition from communicable to noncommunicable diseases, and the recent surge in cardiovascular disorders is one that requires a rapid and adequate public health response.
5
Cardiovascular patients are taking a single medication or combination therapies to control and slowdown the progression of their illness. Cardiovascular drugs are among the most complicated groups of drugs due to overlapping indication, equivalent therapeutic effectiveness and side effects. 6 Wide ranges of cardiovascular medications have been used to manage CVDs including, antihypertensives, lipid-lowering agents, and drugs that ameliorate heart failure.
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Appropriate drug selection and use are crucial to achieving the desired treatment outcomes in various disease state management including CVD. Rational drug use is described by WHO as "Patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community". Therefore, prescribers, dispensers, and users themselves should ensure proper drug use that meets the patient need correctly. [7] [8] [9] [10] Irrational prescribing is one of the malpractices observed during the treatment of cardiovascular disorders. This had been expressed in terms of unjustified drug selection, inappropriate dose, duration, and frequency.
Patients faced additional expenditures from unnecessary drug therapy, improper drug selection or adverse drug events of medication with the wrong indication apart from the direct costs.
11,12
There is quiet controversy on multiple drug therapy indication in cardiovascular patients. The ongoing suggestion is to use multiple drug combination therapy to manage CVDs and for the prevention of cardiovascular events in high-risk groups. 13 In contrary, others argue the combination drug therapy is disregarding the lifestyle modifications for CVDs and still believing in prioritizing lifestyle modification as optimal CVD management and risk prevention. 14, 15 It is proven that both cardiovascular drug therapy and lifestyle modifications are important measures to reduce CVD progression and mortality. 3 Inappropriate use of drugs is the most critical problem in developing countries either at the setting of relatively better health facilities like teaching hospitals or resource-limited health facilities such as general hospitals and health centres where health professionals are scarce. Low economic statuses, illiteracy, lack of skilled clinical experts, and unavailability of drugs have been associated with poor medication selection and utilization. 9 The trend of prescribing practices and pattern of drug utilization in CVD patients is partly based on physicians own perception, perspective, prior experience, and attitude towards a certain class of medication. 
| MATERIAL S AND ME THODS

| Study setting and design
The study setting is located 737 km, northwest from the capital city of Addis Ababa, Ethiopia, which is the largest hospital in the region.
The hospital is selected since it is convenient for data collection and the only hospital in northwestern Ethiopia having the chronic illness clinic of CVDs and other noncommunicable diseases. It is a teaching hospital staffed with diverse expertise from senior specialists in internal medicine, general practitioners to nurses, and other health professionals.
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An institution-based retrospective cross-sectional study was 
| Study population
All patients diagnosed to have CVDs and visited Gondar University Specialized Hospital from January 2011 to December 2016 were the source population. Those patients whose medical records were available were the study population.
| Inclusion and exclusion criteria
The study included all patients diagnosed with CVDs and had the follow-up from January 2011 to December 2016. Patient medical records with incomplete information, patient age below 20 years and lost patient medical records were excluded from the study.
| Data collection, quality control, and management
Data were collected retrospectively from patient medical records by and unreliable data were discarded from the final analysis.
| Data analysis
Data were entered and analyzed using Statistical Package for Social with the number of medications. P value less than 0.05 and 95% confidence interval (CI) were used as cutoff points for determining the statistical significance of associations among different variables.
| Operational definitions
Cardiovascular diseases: is a general category of diseases that affect the heart and circulatory system. It includes hypertension, heart failure, stroke, ischemic heart disease, rheumatic heart disease, hypertensive heart disease, arrhythmia, dyslipidemia, congenital and degenerative heart diseases.
Patients' clinical status on last follow-up will be classified as improved or not improved (poor) based on the following definitions.
Improved: patients had better prognosis by the physician assessment described as good or fair both clinically and in laboratory parameters (signs and symptoms resolved, and other diagnostic parameters improvement or better than initial diagnosis and the previ-
Poor (not improved): there was poor or no prognosis at all or patient clinical conditions might have become worse.
| Ethical approval
Ethical clearance was obtained from the ethical review committee of the college of medicine and health sciences, University of Gondar.
Permission letter was requested from the clinical director of Gondar
University Specialized Hospital and the head of internal medicine was informed before data collection. In addition to these, individual patient data were kept anonymous and confidential by ensuring data taken from medical records were not including any personal identifiers and used only for the purpose of this study.
| RE SULT
| Sociodemographic characteristics
Of 1091 cardiovascular patient medical records, 833 were included in the final analysis with the remaining removed due to incomplete availability of data. 62.5% of patients were females and more than 61% were above 50 years of age. Most of the patients had 3 years (25%), 2 years (29.9%), and 1 year (22.5%) follow-up in the clinic. The majority (41.1%) of patients had a 2-month appointment for the next follow-up (Table 1) .
| Cardiovascular disease distribution and improvement
Two-thirds of cardiovascular patients are hypertensive, followed by heart failure and rheumatic valvular heart disease 9.7% and 7.3%, respectively. Most of the patients (86.6%) had good improvement in the last follow-up as assessed by their physicians.
( Table 2 ).
| Pattern of cardiovascular drug use
Diuretics monotherapy accounted for a third (33.6%) of cardiovascular drug use, followed by combination therapy of angiotensin convertase enzyme inhibitors and diuretics (21.8%) and calcium channel blockers with diuretics (8.3%) ( Table 3) .
Hydrochlorothiazide is the single most commonly prescribed monotherapy followed by Enalapril and Nifedipine, 18.1%, 6.4% and 4.8%, respectively. Hydrochlorothiazide with enalapril (16.2%) and furosemide with spironolactone (11.9%) were the frequently used combined therapies in cardiovascular patients. 8.2% of patients have more than four drugs in their treatment regimens.
( Table 4 ).
| Factors associated with cardiovascular diseases improvement
Being in the age group of 51-60 years was found to be associated with good CVD improvement (the improvement is nearly (Table 5 ).
When cardiovascular patients were followed for 72 months, patients on combination medication found to have a good level of clinical improvement with Log Rank of 28.9, P = 0.000.
( Figure 1 ). 
TA B L
E 2 Cardiovascular disease pattern of patients by diagnosis, GUSH, 2017. (N = 833)
TA B L E 1 Sociodemographic characteristics of cardiovascular patients of GUSH, 2017 (N = 833)
| D ISCUSS I ON
This study presented the retrospective evaluation of the prescribing practices and patterns of cardiovascular drug use in the outpatient department of a University hospital in Ethiopia. Majority of the patients with CVDs in this study were females. Similarly, other studies in Ethiopia showed the proportion of females was higher in CVDs. 5, 8, 26 More than 61% of the patients with CVDs are above 50 years of age, indicating that older age is associated with an increasing occurrence of CVDs. This is due to particularly cardiovascular risk factors rises in a parallel manner with age and age by itself is the nonmodifiable risk factor for CVDs. Modifiable risk factors and lifestyle changes to CVDs are compromised as age increment since aging is an irreversible physiologic process.
29
More than three-fourths of patients had at least 1-3 years of follow-up in the chronic illness clinic. Among those, nearly half of the patients had 1 month or less duration of appointment for follow-up.
Hypertension is the most common cardiovascular disorder followed by heart failure and rheumatic heart disease. This is similar to the pattern of CVDs in previous studies conducted in the same setting and other parts of Ethiopia. 5, [30] [31] [32] [33] Proportionally highest numbers of patients are on diuretics monotherapy or diuretics-based combination therapy. This showed that the majority of cardiovascular patients' treatment relied on diuretics therapy. Hydrochlorothiazide is the most frequently used among diuretics class. This is plausibly acceptable as the Eighth Joint National Committee (JNC 8) recommendation since diuretics-based treatment is the preferred first-line treatment regimen for the black hypertensive patient in which Ethiopia belongs to. 34 A study conducted to identify the recommended heart failure medications revealed that 56% of patients had diuretics in their prescription. 18 The second commonly utilized diuretic in CVDs particularly in heart failure patients is Furosemide as other studies in the Netherlands showed that 80% of congestive heart failure patients were on loop diuretics.
19
In this study hydrochlorothiazide monotherapy is commonly prescribed in nearly a fifth of patients followed by enalapril and nifedipine which is similar to previous studies conducted in Ethiopia and as per Ethiopian standard treatment guideline recommendations but different from the studies in India in which ACE inhibitor and calcium channel blocker monotherapy were the leading monotherapies while calcium channel blockers were the most frequently used drug classes followed by Angiotensin receptor blockers (ARBs) in China.
This might attribute to patient differences in geographical location, physician, and patient preferences and Guideline recommendations. 8, 16, 22, [24] [25] [26] Enalapril and hydrochlorothiazide take the foremost share of dual therapy followed by furosemide with spironolactone combination therapy. One Chinese study to determine the prescribing patterns in hypertension patients reported that ARBs and diuretics were frequent combinations while ARBs were not found to be used in Ethiopian patients 24, 35 Among triple therapies, no significant pattern use and difference were found in cardiovascular patients. Patients who are in more than four medicines were found to be on antiplatelet, anticoagulant, and lipid-lowering agents. These patients are prone to drug interactions, adverse drug reactions, and complications. These polypharmacy prescriptions were found in elderly patients since the CVD incidence and complications rise as age increases. heart diseases which have a poor prognosis and less responsive to medications in the late young ages unless surgically intervened.
36-38
Appointments for next follow-up with 2-month duration were related to the poor cardiovascular outcome. This could be justified as of disease since they are prone to be lost and away from physicians' follow-up. 5 In the present study, combination therapy found to have a good cardiovascular outcome on longer follow-up as compared with single medication therapy. This can be elucidated as combination therapy can optimally control CVDs and prevent further risk of cardiovascular events. The working group on a summit on the combination therapy for CVD publicized that combination drug therapy along with appropriate lifestyle changes can bring an estimated reduction in CVD (70%-80%). 13 Therefore, combination therapy might benefit many individuals and suggested along with other preventive measures.
39-42
| Limitation of the study
Even though it is showing the prescribing trends and cardiovascular drug use which can serve as a foundation for further researches, this was retrospective that could not consider the regimen changes, prognosis throughout the follow-up period of patients and only reflected on the cardiovascular outcome of patients on the last follow-up by their physician assessment. The outcome relied on physician assessment (secondary data) which is prone to interpersonal variability as it depends on physicians' experience, the guideline he/she uses, work experience, expert lever (GP, senior).
Moreover, this study used all cardiovascular drugs used as general and was not tried to relate factors explicitly with separate disease entities. Prospective researches on cardiovascular drug use and patterns peculiar to each CVD is warranted to further understand the implications and to evaluate the appropriateness of drug selection with the existing recommended clinical guidelines. 
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